Technical Analysis for NVO - Novo Nordisk A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| NR7 | Range Contraction | -0.86% | |
| Narrow Range Bar | Range Contraction | -0.86% | |
| Upper Bollinger Band Walk | Strength | -0.86% | |
| Overbought Stochastic | Strength | -0.86% | |
| Gapped Down | Weakness | -0.86% | |
| Upper Bollinger Band Walk | Strength | -2.06% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 1% | 1 day ago |
| Possible NR7 | 2 days ago |
| 2x Volume Pace | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Novo Nordisk A/S Description
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diabetes Pharmaceutical Products Inflammation Obesity Insulin Endocrine System Hormones Peptide Hormones Growth Hormone Diabetes Care Glucagon Like Peptide 1 Growth Hormone Therapy Pharmaceuticals Segment Anti Diabetic Drugs Haemophilia Hormone Therapy Related Delivery Systems
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 137.573 |
| 52 Week Low | 46.5309 |
| Average Volume | 4,105,825 |
| 200-Day Moving Average | 107.96 |
| 50-Day Moving Average | 128.03 |
| 20-Day Moving Average | 128.24 |
| 10-Day Moving Average | 130.06 |
| Average True Range | 2.64 |
| RSI (14) | 58.68 |
| ADX | 17.25 |
| +DI | 33.18 |
| -DI | 21.38 |
| Chandelier Exit (Long, 3 ATRs) | 126.87 |
| Chandelier Exit (Short, 3 ATRs) | 129.21 |
| Upper Bollinger Bands | 134.60 |
| Lower Bollinger Band | 121.87 |
| Percent B (%b) | 0.79 |
| BandWidth | 9.93 |
| MACD Line | 1.79 |
| MACD Signal Line | 1.07 |
| MACD Histogram | 0.7231 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 133.73 | ||||
| Resistance 3 (R3) | 133.59 | 132.83 | 133.42 | ||
| Resistance 2 (R2) | 132.83 | 132.36 | 132.90 | 133.32 | |
| Resistance 1 (R1) | 132.36 | 132.07 | 131.98 | 132.50 | 133.22 |
| Pivot Point | 131.61 | 131.61 | 131.42 | 131.68 | 131.61 |
| Support 1 (S1) | 131.14 | 131.14 | 130.76 | 131.28 | 130.56 |
| Support 2 (S2) | 130.38 | 130.85 | 130.45 | 130.46 | |
| Support 3 (S3) | 129.91 | 130.38 | 130.36 | ||
| Support 4 (S4) | 130.05 |
